Zomedica Corp. Announces Transition to OTCQB Venture Market
Zomedica Corp (NYSE American:ZOM) announced its delisting from the NYSE American exchange and transition to the OTCQB Venture Market, effective March 5, 2025. The company's ticker symbol will change to ZOMDF.
The delisting is due to the NYSE American's determination that Zomedica no longer meets listing requirements under Section 1003(f)(v) of the Company Guide, specifically citing the low selling price of common shares. Despite this change, Zomedica will maintain SEC reporting requirements and continue providing real-time trading data and financial disclosures through OTC Markets.
CEO Larry Heaton emphasized that while disappointed with the delisting, the company's asset value and growth opportunities remain unchanged, with continued focus on developing veterinary products and maintaining investor engagement.
Zomedica Corp (NYSE American:ZOM) ha annunciato il suo delisting dalla borsa NYSE American e il passaggio al OTCQB Venture Market, a partire dal 5 marzo 2025. Il simbolo azionario dell'azienda cambierà in ZOMDF.
Il delisting è dovuto alla determinazione della NYSE American che Zomedica non soddisfa più i requisiti di quotazione ai sensi della Sezione 1003(f)(v) del Company Guide, citando specificamente il basso prezzo di vendita delle azioni ordinarie. Nonostante questo cambiamento, Zomedica manterrà i requisiti di reporting SEC e continuerà a fornire dati di trading in tempo reale e divulgazioni finanziarie attraverso OTC Markets.
Il CEO Larry Heaton ha sottolineato che, sebbene sia deluso per il delisting, il valore degli asset e le opportunità di crescita dell'azienda rimangono invariati, con un continuo focus nello sviluppo di prodotti veterinari e nel mantenimento del coinvolgimento degli investitori.
Zomedica Corp (NYSE American:ZOM) anunció su exclusión de la bolsa NYSE American y su transición al OTCQB Venture Market, efectiva a partir del 5 de marzo de 2025. El símbolo de la empresa cambiará a ZOMDF.
La exclusión se debe a la determinación de la NYSE American de que Zomedica ya no cumple con los requisitos de cotización según la Sección 1003(f)(v) de la Guía de la Empresa, citando específicamente el bajo precio de venta de las acciones comunes. A pesar de este cambio, Zomedica mantendrá los requisitos de informes de la SEC y continuará proporcionando datos de negociación en tiempo real y divulgaciones financieras a través de OTC Markets.
El CEO Larry Heaton enfatizó que, aunque está decepcionado con la exclusión, el valor de los activos y las oportunidades de crecimiento de la empresa permanecen sin cambios, con un enfoque continuo en el desarrollo de productos veterinarios y el mantenimiento del compromiso de los inversores.
조메디카 주식회사 (NYSE American:ZOM)는 2025년 3월 5일부터 NYSE American 거래소에서 상장 폐지되고 OTCQB 벤처 마켓으로 전환한다고 발표했습니다. 회사의 주식 기호는 ZOMDF로 변경됩니다.
상장 폐지는 조메디카가 회사 가이드의 섹션 1003(f)(v)에 따른 상장 요건을 더 이상 충족하지 않는다는 NYSE American의 판단에 따른 것으로, 특히 보통주 판매 가격이 낮다는 점을 언급했습니다. 이러한 변화에도 불구하고 조메디카는 SEC 보고 요건을 유지하고 OTC 마켓을 통해 실시간 거래 데이터와 재무 공시를 계속 제공할 것입니다.
CEO 래리 히튼은 상장 폐지에 실망했지만 회사의 자산 가치와 성장 기회는 변함이 없으며, 계속해서 수의학 제품 개발 및 투자자 참여 유지에 집중할 것이라고 강조했습니다.
Zomedica Corp (NYSE American:ZOM) a annoncé son retrait de la bourse NYSE American et sa transition vers le OTCQB Venture Market, à compter du 5 mars 2025. Le symbole boursier de l'entreprise changera en ZOMDF.
Le retrait est dû à la détermination de la NYSE American que Zomedica ne respecte plus les exigences de cotation selon la section 1003(f)(v) du guide de l'entreprise, citant spécifiquement le faible prix de vente des actions ordinaires. Malgré ce changement, Zomedica continuera de respecter les exigences de reporting de la SEC et continuera à fournir des données de trading en temps réel et des divulgations financières via OTC Markets.
Le PDG Larry Heaton a souligné que, bien qu'il soit déçu par le retrait, la valeur des actifs et les opportunités de croissance de l'entreprise restent inchangées, avec un accent continu sur le développement de produits vétérinaires et le maintien de l'engagement des investisseurs.
Zomedica Corp (NYSE American:ZOM) hat ihre Delistung von der NYSE American Börse und den Übergang zum OTCQB Venture Market zum 5. März 2025 angekündigt. Das Börsensymbol des Unternehmens wird sich in ZOMDF ändern.
Die Delistung erfolgt aufgrund der Feststellung der NYSE American, dass Zomedica die Zulassungsvoraussetzungen gemäß Abschnitt 1003(f)(v) des Company Guide nicht mehr erfüllt, wobei insbesondere der niedrige Verkaufspreis der Stammaktien angeführt wird. Trotz dieser Änderung wird Zomedica die Anforderungen an die SEC-Berichterstattung aufrechterhalten und weiterhin Echtzeit-Handelsdaten und finanzielle Offenlegungen über OTC Markets bereitstellen.
CEO Larry Heaton betonte, dass er zwar über die Delistung enttäuscht sei, der Wert der Vermögenswerte und die Wachstumschancen des Unternehmens jedoch unverändert bleiben, mit einem fortgesetzten Fokus auf die Entwicklung von Veterinärprodukten und die Aufrechterhaltung des Engagements der Investoren.
- Company maintains SEC reporting and transparency
- Continues normal business operations and product development
- Delisted from NYSE American due to low share price
- Downgrade to less prestigious OTCQB market may reduce institutional investment
- Potential decrease in stock liquidity and trading volume
Zomedica's ticker symbol will change to ZOMDF
ANN ARBOR, MI / ACCESS Newswire / March 4, 2025 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a leading veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced that its common shares will be delisted from the NYSE American exchange, due to their determination that the Company is no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the common shares.
Zomedica has made arrangements with the OTCQB Venture Market for its shares to begin trading on the OTCQB Venture Market exchange under the ticker symbol "ZOMDF", effective March 5, 2025.
"While we are disappointed by the delisting of our common shares from NYSE American, this transition to the OTCQB Market continues to allow Zomedica to maintain its strong engagement with investors while allowing us to focus our resources on driving growth and advancing our pipeline of veterinary products," said Larry Heaton, Chief Executive Officer of Zomedica. "While our common shares will be trading on OTCQB, the value of the company's assets, and our opportunities for growth remain the same. We remain dedicated to delivering value to our shareholders and the veterinary community as we continue to innovate in the animal health sector."
The company will continue to file periodic reports with the U.S. Securities and Exchange Commission (SEC) and comply with applicable regulatory requirements.
Shareholders and investors will continue to have access to real-time trading data, news, and financial disclosures through the OTC Markets website (www.otcmarkets.com) and Zomedica's investor relations page.
About Zomedica Corp.
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW™ digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the anticipated transition to the OTCQB Market and the company's business outlook. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially. Factors that may impact future results include, but are not limited to, market conditions, regulatory approvals, and competitive developments. Zomedica disclaims any obligation to update or revise forward-looking statements except as required by law.
Investor & Media Contact:
Investor Relations
investors@zomedica.com
(734) 369-2555 extension #5
SOURCE: Zomedica Corp.
View the original press release on ACCESS Newswire
FAQ
When will Zomedica (ZOM) begin trading on OTCQB Venture Market?
Why is Zomedica (ZOM) being delisted from NYSE American?
What will be Zomedica's new stock symbol after NYSE delisting?
Will Zomedica continue SEC reporting after moving to OTCQB?
